Maternal care for anti-D [Rh] antibodies, second trimester (fetus 1)
ICD-10 O36.0121 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, second trimester (fetus 1).
O36.0121 refers to maternal care for a pregnancy complicated by the presence of anti-D (Rh) antibodies during the second trimester for the first fetus. This condition arises when an Rh-negative mother carries an Rh-positive fetus, leading to the potential for hemolytic disease of the newborn (HDN). The presence of these antibodies can cause fetal complications such as anemia, jaundice, and in severe cases, fetal distress or intrauterine growth restriction (IUGR). Monitoring and management strategies may include regular ultrasound assessments to evaluate fetal growth and well-being, as well as potential interventions like intrauterine transfusions if significant anemia is detected. The management of anti-D antibodies is crucial to prevent adverse outcomes and ensure the health of both mother and fetus throughout the pregnancy.
Detailed records of maternal blood tests, ultrasound findings, and any interventions performed.
Routine monitoring of fetal growth in pregnancies complicated by anti-D antibodies.
Accurate coding requires understanding of the timing of antibody testing and its implications for fetal health.
Comprehensive documentation of high-risk assessments, including detailed ultrasound reports and management plans.
Management of severe fetal anemia due to Rh incompatibility requiring intrauterine transfusion.
High-risk pregnancies necessitate thorough documentation of all interventions and outcomes.
Used to monitor fetal growth and well-being in pregnancies with anti-D antibodies.
Ultrasound reports must detail findings related to fetal growth and any signs of distress.
Obstetricians must ensure that ultrasound findings are clearly linked to the diagnosis of anti-D antibodies.
Anti-D antibodies can lead to hemolytic disease of the newborn, causing complications such as anemia, jaundice, and in severe cases, fetal distress or intrauterine growth restriction. Regular monitoring and appropriate interventions are crucial to manage these risks.
